Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.

Driven by Science

Rapid, efficient, cost-effective approach

Our expert team is skilled at identifying promising drug candidates and advancing them through all stages of drug development.

More...

Focused on Life

Developing novel small molecule drugs for serious diseases

We aim to transform the treatment of neurologic diseases and cancer and offer hope to patients and their caregivers.

More...

MDV3100

First in class, oral androgen receptor signaling inhibitor (ARSI) candidate in Phase 3 development for advanced prostate cancer

Based on the mechanism of MDV3100, we believe it could be useful in a broad spectrum of prostate cancer disease states, with the first step to develop it for patients with the most advanced disease and in greatest need.

More...

News & Recent Releases

Tuesday, January 17, 2012

Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon in Alzheimer's Disease
Monday, January 9, 2012

Data From Phase 3 AFFIRM Trial of MDV3100 in Advanced Prostate Cancer to Be Highlighted in Late-Breaking Presentation at ASCO GU